{
}
Sartorius AG, a Germany-based supplier of pharmaceutical and laboratory equipment, is poised for strong performance in FY25 as bioprocessing demand rebounds, according to Barclays. The company operates in two segments: bioprocess solutions, which includes integrated manufacturing solutions for biopharmaceuticals, and lab products and services, offering a range of laboratory instruments and consumables.
Barclays has upgraded Sartorius AG and its subsidiary Sartorius Stedim Biotech to Overweight, citing a post-COVID recovery in the bioprocessing industry. The firm notes both stocks are undervalued compared to peers, with SRT expected to see 12% order growth in FY25 and a significant increase in free cash flow. Price targets have been raised for both companies, reflecting anticipated positive earnings momentum as customer demand returns.
Sartorius is poised for a recovery in 2025 after a challenging year, with expectations of profitable and moderate growth across both divisions. The company reported stable annual revenue of €3.38 billion and a strong fourth quarter, achieving €907 million in sales, a 6.5% increase year-over-year. Analysts have varied ratings, with JPMorgan maintaining an "Overweight" stance and a target price of €230, while UBS raised its target to €302 but kept a "Neutral" rating.
UBS AG has maintained a "Neutral" rating for Sartorius vz shares, setting a target price of 280 euros following strong fourth-quarter results that surpassed expectations, particularly in order intake. The share price rose by 12.3% to EUR 281.00, reflecting a 30.6% increase since the start of 2025. Key figures for Q4 2024 are set to be released on January 28, 2025.
UBS has maintained a "Neutral" rating for Sartorius vz shares with a price target of €280, following a strong fourth quarter that exceeded expectations, particularly in order intake. The share price rose 12.2% to €280.80, reflecting a 30.5% gain since the start of 2025, despite a slight downside risk. The Q4 2024 financial results are set to be released on January 28, 2025.
The Growth Factors Market is influenced by strategic mergers, consumer shifts towards sustainability, and advancements in data analytics. Key challenges include cybersecurity risks and skilled labor shortages, while opportunities lie in personalized e-commerce and renewable energy solutions. Major players like Johnson & Johnson and Thermo Fisher Scientific are shaping the competitive landscape through innovation and market expansion.
Sartorius shares are trading at 202.00 euros, reflecting a slight decline of 0.37%, but are up 0.27% for the month. UBS has raised its price target from 194 to 215 euros while maintaining a "Hold" rating, indicating cautious optimism amid a potential recovery in the biotechnology sector. Investors are advised to monitor upcoming developments closely, as they may impact short-term share price momentum.
UBS AG has raised its price target for Sartorius from 264 to 278 euros while maintaining a "Neutral" rating, citing higher industry valuations. Despite a 0.2% drop in share price to EUR 252.90, there remains a potential upside of 9.92%. Sartorius vz shares have decreased by 23.9% since the start of 2024, with Q4 2024 results expected on January 23, 2025.
UBS has raised its target price for Sartorius to €278, maintaining a 'Neutral' rating. The stock closed at €263.00, reflecting a 3.22% increase on the day, with trading activity across various exchanges showing slight variations in price. The annual high for Sartorius stands at €383.70, while the low is €199.50.
UBS has increased its price target for Sartorius from 264 to 278 euros following the release of third-quarter figures, maintaining a "Neutral" rating. Analyst Matthew Weston attributed the adjustment to generally higher valuations within the laboratory services industry.
Sartorius AG
Companies
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
sartorius ag poised for growth as bioprocessing demand increases in fy25
18:20 26.02.2025
Barclays Upgrades Sartorius AG and Subsidiary on Post-COVID Recovery Potential
16:06 26.02.2025
sartorius reports strong fourth quarter and optimistic outlook for 2025
Euro
JPMorgan Chase & Co.
Warburg Research GmbH
Deutsche Bank RV Global PP
Sartorius AG
USA
DEU
CHE
Richard Vosser
Falko Friedrichs
Marion Schlegel
Michael Heider
Matthew Weston
James Vane-Tempest
Delphine Le Louet
Show more
07:28 29.01.2025
ubs maintains neutral rating on sartorius vz shares with target price of 280 euros
11:28 28.01.2025
ubs maintains neutral rating for sartorius vz shares with price target of 280 euros
10:28 28.01.2025
Growth Factors Market Insights Opportunities and Challenges in Emerging Industries
Lonza Group AG
Sartorius AG
Merck & Co., Inc.
Thermo Fisher Scientific Inc.
Johnson & Johnson Services Inc.
F. Hoffmann-La Roche SA
Show more
14:46 06.12.2024
Sartorius shares show resilience amid cautious optimism from UBS
13:58 22.10.2024
ubs raises sartorius price target to 278 euros maintains neutral rating
10:43 22.10.2024
ubs raises sartorius price target to 278 euros maintaining neutral stance
09:53 22.10.2024
UBS raises Sartorius price target to 278 euros maintains neutral rating
09:53 22.10.2024
Trending
Subcategory
Industry Trends
Corporate News
Startups & Entrepreneurship
Supply Chain Management
Global Trade Developments
Industry Mergers & Acquisitions
Government Economic Policies
Cryptocurrency Trends
Financial Scams and Security
Workplace Trends
Retail and Consumer Goods
CEO Changes
Venture Capital Investments
Finance Mergers & Acquisitions
Funding Rounds & Investments
Fintech Startups
Emerging Startups
Consumer Protection Regulations
Market Analysis and Predictions
Energy Sector Developments
Countries:
Companies:
Apple Inc.
Google Inc.
NVIDIA Corporation
Delhivery Limited
Ecom Express Ltd.
Alphabet Inc.
OpenAI ERC USD
Ciscom Corp.
ERICSSON - CLASS B
Physicswallah Ltd.
Snap Inc.
Tiktok USD
Semiconductor Manufacturing International Corporation
Hua Hong Semiconductor Ltd.
Spotify Technology S.A.
Dropbox, Inc.
Vimeo, Inc.
Adobe Inc.
Airbnb, Inc.
SpaceXCoin USD
Currencies:
United States Dollar
Indian Rupee
Chinese Yuan
Euro
Vietnamese Đồng
Russian Ruble
South Korean Won
Pakistani Rupee
Algerian Dinar
Australian Dollar
Thai Baht
New Taiwan Dollar
United Arab Emirates Dirham
People: